Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at riskNovo Nordisk takes decisive legal action to stop Hims’ illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetesNovo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that inf ...

Core Insights - Novo Nordisk has terminated its collaboration with Hims & Hers Health, Inc. due to non-compliance with legal standards regarding the sale of compounded drugs, which poses risks to patient safety [1][2][8] - The FDA has confirmed that Novo Nordisk is meeting the current and projected demand for Wegovy®, resolving previous shortages [2] - Novo Nordisk emphasizes the importance of providing authentic, FDA-approved Wegovy® to patients and is committed to working with telehealth companies that prioritize patient safety [3][8] Company Actions - Novo Nordisk will no longer provide Wegovy® through Hims & Hers Health, Inc. due to their deceptive marketing practices and illegal sales of compounded drugs [1][2][8] - The company is taking proactive measures to protect U.S. patients from unsafe knock-off drugs made with illicit foreign ingredients, particularly those sourced from unapproved suppliers in China [3][8] - Novo Nordisk aims to ensure that patients receive authentic Wegovy® through NovoCare® Pharmacy, which offers home delivery and support services [6][8] Industry Context - Obesity is recognized as a serious chronic disease affecting approximately 40% of adults in the U.S., necessitating long-term management and treatment options [5][23] - The prevalence of obesity has significant implications for healthcare systems, highlighting the need for effective and safe treatment options like Wegovy® [5][23] - The collaboration between telehealth companies and pharmaceutical firms is critical in providing access to regulated medications, but must adhere to legal and safety standards to protect patients [2][3][8]